Last updated on March 2019

A Study of Subjects With Psoriatic Arthritis to Investigate the Effectiveness of Adalimumab Introduction Compared With Methotrexate Dose Escalation (CONTROL)

Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

  • Age: Between 18 - 100 Years
  • Gender: Male or Female

Inclusion Criteria:

  1. PsA diagnosis established at least 4 weeks prior to the date of the Screening visit and confirmed by ClASsification of Psoriatic Arthritis (CASPAR) criteria
  2. Not in MDA at the time of screening
  3. Has 3 or more tender and 3 or more swollen joints
  4. Treated with methotrexate 15 mg (weekly) for at least 4 weeks

Exclusion Criteria:

  1. Contraindications to adalimumab therapy and/or known hypersensitivity to adalimumab or its excipients
  2. History of methotrexate intolerance/toxicity
  3. Medical conditions(s) precluding methotrexate dose increase above 15 mg
  4. Had prior exposure to any tumor necrosis factor (TNF) inhibitor, other mechanism of action biologic DMARD (bDMARD) or any systemic biologic agent in general

Recruitment Status: Open

Brief Description Eligibility Contact Research Team

Receive Emails About New Clinical Trials!

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.